Mylan Scores PTAB Review Of Teva’s Copaxone Patents

Teva's three-times-a-week Copaxone has been key to its franchise protection; now that defense could quickly come under generic threat as well.

Mylan Pharmaceuticals Inc. won the chance to knock out patents covering Teva Pharmaceutical Industries Ltd.’s new 40 mg/mL dosage of Copaxone (glatiramer) through the speedy inter partes review process.

The Patent and Trademark Office’s Patent Trial and Appeal Board issued a pair of Aug. 25 decisions instituting review of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

Drug Distributors Face Aug. 27 Deadline For Electronic Exchange Of Product Tracking Data

 
• By 

Compliance deadline comes three months after manufacturers were required to start sending accurate, electronic product tracking data to distributors. The Healthcare Distribution Alliance said its members are ready and it does not anticipate major supply chain issues.

Pharma’s Move Into Direct-To-Patient Sales Facing Legal, Practical and Political Hurdles

 
• By 

Only a handful programs by pharmaceutical firms are in operation so far. Some companies may be waiting to see if a broad government-facilitated DTC initiative will materialize.

US Policy Shift Sparks German Contingency Plans For Accessing ClinicalTrials.gov, PubMed

IQWiG, Germany’s health technology assessment body, is making contingency plans in case key US resources it relies on for information retrieval, when conducting benefit assessments of new medicines, become unavailable.

Indegene Exec On DTP Distribution As A ‘Tactical Solution’, Feasibility Of MFN Model

 

Senior Indegene executive William Lobb talks about complexities of the direct-to-patient distribution model in the US, including potentially introducing new intermediaries into the system. Questions on MFN's feasibility and why it may be “catastrophic” to biopharma were also part of the discussion

More from North America

Best Laid Plans: A Chronology Of Post-Pandemic COVID-19 Vaccines

 

Quick responses to late-breaking changes to US FDA COVID-19 vaccine policy kept Novavax's Nuvaxovid and Moderna's mNexspike close to expected approval timelines despite revised indications and new post-marketing trial commitments.

Last Minute Course Shifts, Focus On Unknowns: What Sponsors Should Learn From Prasad’s Interventions

 

The once and current CBER director’s justification for his COVID-19 decision stands as a warning of the uncertainty sponsors, particularly those in the vaccine space, may now face at FDA.

GLP-1s In Crosshairs As Employers Worry About Health Costs – And Their Own Reliance On Rebates

 
• By 

Business Group on Health annual employer survey highlights fast-growing Rx costs, led by the GLP-1 drugs, and payer strategies for controlling them. Policy prescriptions are unclear, though, since employers are loath to leave PBMs and nervous about pending changes to Medicare and Medicaid.